Position in GILD
as of Jun 30, 2026
· filed Jul 22, 2026
Position Value
$427,281
-$96,332 QoQ
Shares Held
3,382
-10.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#1,456
of 2,266 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 5%
Shared 0%
None 95%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Canopy Partners, LLC holds $13,071,553 across 11 Drug Manufacturers - General names. GILD ranks #9 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
13,071 | $3,319,641 | |
| 2 | LLY |
ELI LILLY & Co
|
1,784 | $2,139,783 | |
| 3 | MRK |
Merck & Co., Inc.
|
13,530 | $1,738,605 | |
| 4 | AMGN |
Amgen Inc
|
4,519 | $1,636,420 | |
| 5 | ABBV |
AbbVie Inc.
|
5,423 | $1,364,643 | |
| 6 | PFE |
Pfizer Inc
|
36,141 | $870,275 | |
| 7 | NVS |
Novartis AG
|
3,458 | $541,937 | |
| 8 | AZN |
Astrazeneca PLC
|
2,702 | $512,353 |
All Filings in GILD
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $427,281 | 3,382 | Shares | Sole | 2026-07-22 | |
| 2026-03-31 | $523,613 | 3,757 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $424,066 | 3,455 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $363,858 | 3,278 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $388,377 | 3,503 | Shares | Sole | 2025-07-23 | |
| 2025-03-31 | $392,511 | 3,503 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $408,552 | 4,423 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $367,219 | 4,380 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $308,401 | 4,495 | Shares | Sole | 2024-08-09 | |
| 2024-03-31 | $297,395 | 4,060 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $297,063 | 3,667 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||